Serum Lipid Profile in Patients With Primary Adrenal Insufficiency Receiving Glucocorticoid Replacement
Authors' conclusion
The risk of hyperlipidemia in patients receiving GC replacement does not seem elevated.
Study context
- Population
- Patients treated for autoimmune Addison's disease (AD), excluding diabetes, thyroid dysfunction and lipid-lowering treatment; all on immediate-release hydrocortisone
- Participants
- 66 / 97 / 96
- Exposure
- Autoimmune AD on glucocorticoid (GC) replacement vs matched controls
- AD1n = 66
- AD2n = 97
- Controls (CON)n = 96reference
- Outcome
- Serum lipids
Methodological detailsmatched controls
- Matched controls
Main finding
As reported in the abstract
Hyperlipidemia
AD1 vs CON: P = 0.032 · AD2 vs CON: P = 0.811
- Only HDL-C was significantly higher in AD2
- P = 0.009
Observational data: associations, not effects.
Further findings
Hydrocortisone (HC) dose
- HC dose, all patients
- mean ± SD 22.7 ± 6.6 mg/day
- AD1 significantly lower HC dosage vs AD2 and CON
- P ≤ 0.001
TSH and fasting glucose
- AD1 higher TSH vs AD2 and CON
- P ≤ 0.046
- AD1 lower fasting glucose vs AD2 and CON
- P ≤ 0.005
Correlates of lipids
- Age strongly correlated with total cholesterol (TC) and LDL-C in AD and CON
- Daily HC dose correlated with TC and LDL-C in AD1 and AD2, and with HDL-C in AD1; multivariable regression confirmed its predictive value for TC and LDL-C
Original publication
Serum Lipid Profile in Patients With Primary Adrenal Insufficiency Receiving Glucocorticoid Replacement. Clin Endocrinol (Oxf). Published 26 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →